Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125
NCT ID: NCT01436734
Last Updated: 2015-07-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
5 participants
INTERVENTIONAL
2011-07-31
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes
NCT00704795
Neuronostatin - a Glucagonotropic Agent in Humans?
NCT06143267
Physiologic Response to Glucagon at Varying Insulin Levels
NCT01483651
Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance
NCT02475421
The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes
NCT06881472
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GIP
Fasting glycemia
no intervention
Hypoglycemia
Insulin induced hypoglycemia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fasting glycemia
no intervention
Hypoglycemia
Insulin induced hypoglycemia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Liver disease (ALAT/ASAT \>2 x upper normal limit)
* Diabetic nephropathy (s-creatinine \>130 µM or albuminuria)
* Proliferative diabetic retinopathy (anamnestic)
* Severe arteriosclerosis or heart failure (NYHA group III og IV)
* Anemia
* treatment with medication not applicable to pause for 12 hours
* pregnancy or lactation
* Fasting plasma glucose \>15 mM on screening day.
18 Years
70 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Gentofte, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mikkel Christensen
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mikkel Christensen, MD
Role: PRINCIPAL_INVESTIGATOR
Gentofte Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gentofte Hospital
Hellerup, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-D-2009-0078
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.